Empagliflozin Effectively Lowers Liver Fat Content in Well-Controlled Type 2 Diabetes: A Randomized, Double-Blind, Phase 4, Placebo-Controlled Trial
Open accessThe DOI matches its Crossref record; 42 of the 43 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To evaluate whether the sodium–glucose cotransporter 2 inhibitor empagliflozin (EMPA) reduces liver fat content (LFC) in recent-onset and metabolically well-controlled type 2 diabetes (T2D). RESEARCH DESIGN AND METHODS: Patients with T2D (n = 84) (HbA1c 6.6 ± 0.5% [49 ± 10 mmol/mol], known disease duration 39 ± 27 months) were randomly assigned to 24 weeks of treatment with 25 mg daily EMPA or placebo. The primary end point was the difference of the change in LFC as measured with magnetic resonance methods from 0 (baseline) to 24 weeks between groups. Tissue-specific insulin sensitivity (secondary outcome) was assessed by two-step clamps using an isotope dilution technique. Exploratory analysis comprised circulating surrogate markers of insulin sensitivity and liver function. Statistical comparison was done by ANCOVA adjusted for respective baseline values, age, sex, and BMI. RESULTS: EMPA treatment resulted in a placebo-corrected absolute change of −1.8% (95% CI −3.4, −0.2; P = 0.02) and relative change in LFC of −22% (−36, −7; P = 0.009) from baseline to end of treatment, corresponding to a 2.3-fold greater reduction. Weight loss occurred only with EMPA (placebo-corrected change −2.5 kg [−3.7, −1.4]; P < 0.001), while no placebo-corrected change in tissue-specific insulin sensitivity was observed. EMPA treatment also led to placebo-corrected changes in uric acid (−74 mol/L [−108, −42]; P < 0.001) and high-molecular-weight adiponectin (36% [16, 60]; P < 0.001) levels from 0 to 24 weeks. CONCLUSIONS: EMPA effectively reduces hepatic fat in patients with T2D with excellent glycemic control and short known disease duration. Interestingly, EMPA also decreases circulating uric acid and raises adiponectin levels despite unchanged insulin sensitivity. EMPA could therefore contribute to the early treatment of nonalcoholic fatty liver disease in T2D.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Of note, the amount of weight loss determined the amount of liver lipid reduction for both empagliflozin [98] and canagliflozin [155] in respective RCTs.”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Notably, weight loss-mediated improvement of MASLD-related steatosis did not necessarily depend on normalization of glycemia in RCTs with caloric restriction or sodium-glucose co-transporter 2 inhibitor (SGLT2I) treatment [97][98][99].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“whereas both dapagliflozin and empagliflozin were able to reduce liver lipid content in people with type 2 diabetes with (dapagliflozin [153,154]) or both with and without MASLD (empagliflozin [98]).”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Further, in another RCT, empagliflozin led to a placebocorrected 2.3-fold greater reduction in liver lipid content and a 36 % increase in plasma adiponectin levels in people with type 2 diabetes and short diabetes duration, despite unchanged fasting glycemia and tissuespecific insulin sensitivity [4,98].”
From Obesity and MASLD: Is weight loss the (only) key to treat metabolic liver disease? (2024) · cites this paper as [98]
In the citing paper
“Trials in people with T2D (not all with MASLD and some excluding high ALT values) have shown a moderate reduction in liver lipid content with empagli fl ozin, 414,415 dapagli fl ozin 416 and licoglifl ozin.”
From EASL-EASD-EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). (2024) · cites this paper as [415]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Missing data: our view of the state of the art
Schafer, J. L., & Graham, J. W. (2002) · Psychological Methods · doi:10.1037/1082-989x.7.2.147 · Cited by 11,638
Standards of Medical Care in Diabetes
Power, D. (2006) · Diabetes Care · doi:10.2337/diacare.29.02.06.dc05-1593 · Cited by 8,673
Standards of medical care in diabetes—2014
American Diabetes Association (2014) · Diabetes Care · doi:10.2337/dc14-s014 · Cited by 4,572
A short questionnaire for the measurement of habitual physical activity in epidemiological studies
Baecke, J., Burema, J., & Frijters, J. (1982) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/36.5.936 · Cited by 3,945
Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Szczepaniak, L. S., Nurenberg, P., Leonard, D., Browning, J. D., Reingold, J. S., Grundy, S., Hobbs, H. H., & Dobbins, R. L. (2005) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00064.2004 · Cited by 1,562 · cited 1×
“56% [21]) occurred in 5 (20%) of 25 patients in the EMPA group and 2 (8%) of 24 patients in the placebo group at 24 weeks.”
BackgroundTreatment of NAFLD with diet, physical activity and exercise
Romero-Gómez, M., Zelber-Sagi, S., & Trenell, M. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.05.016 · Cited by 1,347 · cited 1×
“02) and relative decrease in LFC (222% [236, 27]; P 5 0.”
BackgroundMetabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Tilg, H., Moschen, A. R., & Roden, M. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2016.147 · Cited by 1,002
Self-citationDapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Cited by
Items 101–200 of 370
Perakakis, N., Chrysafi, P., Feigh, M., Veidal, S. S., & Mantzoros, C. S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126332 · Cited by 34
“The a priori hypothesis was based on the fact that no detrimental effects of empagliflozin on the liver function have been reported so far: (a) in numerous animal studies (in models with and without NAFLD); (b) in human Phase II and Phase III randomized clinical trials (RCTs) with patients with NAFLD and T2DM includin…”
BackgroundPharmacotherapy for metabolic dysfunction-associated steatohepatitis: heart–liver co-management
Zhou, X., Lazarus, J. V., Krittanawong, C., Targher, G., Byrne, C. D., Younossi, Z. M., Tacke, F., Chen, Q., Mantzoros, C. S., Tilg, H., et al. (2026) · The Lancet. Gastroenterology & hepatology · doi:10.1016/s2468-1253(25)00323-1 · Cited by 50
Self-citationZong, J., Sun, Y., Zhang, Y., Yuan, J., Wang, X., Zhang, R., Zhao, X., Zhao, X., & Gu, Y. (2020) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s260891 · Cited by 37
Clinical implications, diagnosis, and management of diabetes in patients with chronic liver diseases
Chung, W., Promrat, K., & Wands, J. R. (2020) · World Journal of Hepatology · doi:10.4254/wjh.v12.i9.533 · Cited by 36
Xie, L., & Wenfang, X. (2022) · Life Sciences · doi:10.1016/j.lfs.2022.120543 · Cited by 36
Hu, Y., Sun, C., Chen, Y., Liu, Y., & Fan, J. (2024) · Journal of Clinical and Translational Hepatology · doi:10.14218/jcth.2024.00123 · Cited by 61
“26,59 The efficacy of SGLT2i in reducing”
Metabolic reprogramming of immune cells in MASH
Ma, C., Wang, S., Dong, B., & Tian, Y. (2025) · Hepatology · doi:10.1097/hep.0000000000001371 · Cited by 35
Sodium-glucose co-transporter 2 inhibitors in nonalcoholic fatty liver disease
Makri, E. S., Goulas, A., & Pοlyzos, S. A. (2021) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2021.174272 · Cited by 32
Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: A comprehensive review
Shakour, N., Karami, S., Iranshahi, M., Butler, A. E., & Sahebkar, A. (2023) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2023.102934 · Cited by 35
Authors, & Collaborators: (2022) · Zeitschrift für Gastroenterologie · doi:10.1055/a-1880-2388 · Cited by 30
Giannakogeorgou, A., & Roden, M. (2024) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.17848 · Cited by 30
“140,142,147 The positive effects of SGLT2i in on cardiovascular and renal outcomes in people with T2D are well-established.”
BackgroundSelf-citationEffects and potential mechanisms of IGF1/IGF1R in the liver fibrosis: A review
Gui, R., Li, W., Li, Z., Wang, H., Wu, Y., Jiao, W., Zhao, G., Shen, Y., Wang, L., Zhang, J., et al. (2023) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.126263 · Cited by 35
Cardiovascular Disease in Nonalcoholic Steatohepatitis: Screening and Management
Shroff, H., & VanWagner, L. B. (2020) · Current Hepatology Reports · doi:10.1007/s11901-020-00530-0 · Cited by 35
p53: from understanding its structure to advances in therapeutic targeting
Wang, W., Liu, X., Liu, H., Abolhassani, H., Yan, H., Zhang, H., & Wang, X. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02549-5 · Cited by 30
Hyperuricemia-induced complications: dysfunctional macrophages serve as a potential bridge
Gu, W., Zhao, J., & Xu, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1512093 · Cited by 36
Rroji, M., Spahia, N., Figurek, A., & Spasovski, G. B. (2025) · Biomedicines · doi:10.3390/biomedicines13030728 · Cited by 34
“As for empagliflozin, this treatment did not significantly alter IL-6 levels in subjects with T2DM [244], although a distinct trial in patients with T2DM with reduced ejection fraction (HFrEF) reported a significant decrease [245].”
Belli, M., Barone, L., Bellia, A., Sergi, D., Lecis, D., Prandi, F. R., Milite, M., Galluccio, C., Muscoli, S., Romeo, F., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232314598 · Cited by 29
Luo, Q., Wei, R., Cai, Y., Zhao, Q., Liu, Y., & Liu, W. J. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.793203 · Cited by 28
Konings, L. A. M., Matute, L. M., Boeren, A. M. P., van de Luitgaarden, I. A. T., Dirksmeier-Harinck, F., de Knegt, R. J., Tushuizen, M. E., Grobbee, D. E., Holleboom, A. G., & Cabezas, M. C. (2025) · European Journal of Clinical Investigation · doi:10.1111/eci.70003 · Cited by 34
Armandi, A., & Schattenberg, J. M. (2021) · Nutrients · doi:10.3390/nu13061977 · Cited by 31
Diaconu, C.-T., & Guja, C. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175144 · Cited by 33
Kaylan, K. B., & Paul, S. (2024) · Current Diabetes Reports · doi:10.1007/s11892-024-01558-y · Cited by 34
Misra, A., Kumar, A., Kuchay, M. S., Ghosh, A., Gulati, S., Choudhary, N. S., Dutta, D., Sharma, P., Vikram, N. K., Rastogi, A., et al. (2025) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2025.103209 · Cited by 28
Samson, S. L., Vellanki, P., Blonde, L., Hirsch, I. B., Hoang, T. D., Isaacs, S. D., Izuora, K. E., Wang, C. C. L., Ooi, C. P., Padilla, B. I., et al. (2026) · Endocrine Practice · doi:10.1016/j.eprac.2026.01.006 · Cited by 33
Aragón‐Herrera, A., Moraña‐Fernández, S., Otero-Santiago, M., Anido‐Varela, L., Campos‐Toimil, M., García‐Seara, J., Roman, A. V., Seijas‐Amigo, J., García‐Caballero, L., Rodríguez, J., et al. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114535 · Cited by 29
The impact of sodium glucose co‐transporter 2 inhibitors on non‐alcoholic fatty liver disease
Chrysavgis, L., Papatheodoridi, A., Chatzigeorgiou, A., & Cholongitas, Ε. (2020) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15202 · Cited by 29
Sinha, B., Datta, D., & Ghosal, S. (2020) · JGH Open · doi:10.1002/jgh3.12473 · Cited by 27
Bönhof, G. J., Strom, A., Apostolopoulou, M., Karusheva, Y., Sarabhai, T., Pesta, D. H., Roden, M., & Ziegler, D. (2022) · Diabetologia · doi:10.1007/s00125-022-05674-w · Cited by 27
Self-citationDrug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Zhou, D., & Fan, J. (2024) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003355 · Cited by 30
Colosimo, S., Tan, G. D., Petroni, M. L., Marchesini, G., & Tomlinson, J. (2022) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2022.12.010 · Cited by 32
NAFLD and type 2 diabetes: A practical guide for the joint management
Genua, I., Iruzubieta, P., Rodríguez-Duque, J. C., Pérez, A., & Crespo, J. (2022) · Gastroenterología y Hepatología · doi:10.1016/j.gastrohep.2022.12.002 · Cited by 25
Song, T., Chen, S., Zhao, H., Wang, F., Song, H., Tian, D., Yang, Q., & Qi, L. (2021) · Hepatology Research · doi:10.1111/hepr.13645 · Cited by 23
Ma, Y., Kan, C., Qiu, H., Liu, Y., Hou, N., Han, F., Shi, J., & Sun, X. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.793586 · Cited by 25
“…trials have reported SGLT2i had beneficial effects on NAFLD, as evidenced by the remarkably reduced ALT, AST, triglycerides, hepatic insulin Frontiers in Pharmacology | www.frontiersin.org December 2021 | Volume 12 | Article 7935868 sensitivity indices (Ranjbar et al., 2019; Kahl et al., 2020).”
BackgroundLara, C., & Romero‐Gómez, M. (2024) · European Cardiology Review · doi:10.15420/ecr.2023.34 · Cited by 25
Pecani, M., Andreozzi, P., Cangemi, R., Corica, B., Miglionico, M., Romiti, G. F., Stefanini, L., Raparelli, V., & Basili, S. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082750 · Cited by 29
Euh, W., Lim, S. K., & Kim, J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.613389 · Cited by 25
Amin, M. A., Sadik, N. A., Saad, H. A., Fawzy, M., & Elsheimy, H. A. (2025) · Internal and Emergency Medicine · doi:10.1007/s11739-025-03902-w · Cited by 24
Boulos, M., Mousa, R. S., Jeries, N., Simaan, E., Alam, K., Bulus, B., & Assy, N. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26073448 · Cited by 26
“…al., which reported that Em-pagliflozin (25 mg) reduced liver fat content in T2D patients with MASLD, confirmed by magnetic resonance spectroscopy [173]; Shimizu et al.’s study, which reported dapagliflozin (5 mg/day) to result in significant reductions in liver fat and liver stiffness, which was…”
Anti-diabetic drugs and NASH: from current options to promising perspectives
Smati, S., Canivet, C. M., Boursier, J., & Cariou, B. (2021) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2021.1951701 · Cited by 22
Therapies for non-alcoholic fatty liver disease: A 2022 update
Shen, K., Singh, A. D., Esfeh, J. M., & Wakim-Fleming, J. (2022) · World Journal of Hepatology · doi:10.4254/wjh.v14.i9.1718 · Cited by 27
Outcomes of SGLT-2i and GLP-1RA Therapy Among Patients With Type 2 Diabetes and Varying NAFLD Status
Bea, S., Jeong, H. E., Filion, K. B., Yu, O. H., Cho, Y. M., Lee, B. H., Chang, Y., Byrne, C. D., & Shin, J. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.49856 · Cited by 25
Vincent, R. K., Williams, D. M., & Evans, M. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14196 · Cited by 22
“101 This was a relatively well-designed study and was placebo-controlled, with uric acid and adiponectin levels collected to explain the findings.”
BackgroundManka, P. P., Kaya, E., Canbay, A. E., & Syn, W. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-021-07206-9 · Cited by 23
What’s new in non-alcoholic fatty liver disease?
Spiers, J., Brindley, J. H., Li, W., & Alazawi, W. (2022) · Frontline Gastroenterology · doi:10.1136/flgastro-2022-102122 · Cited by 26
Pharmacotherapies of NAFLD: updated opportunities based on metabolic intervention
Shao, Y., Chen, S., Liu, H., & Liu, J. (2023) · Nutrition & Metabolism · doi:10.1186/s12986-023-00748-x · Cited by 21
“Another GLP-1 receptor agonist, exenatide, stimulates β-oxidation and conversely downregulates genes related to lipogenesis, ultimately improving NAFLD [193, 194].”
BackgroundAltered lipid metabolism and the development of metabolic-associated fatty liver disease
Foster, C., Gagnon, C. A., & Ashraf, A. P. (2024) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000933 · Cited by 19
Hepatitis C virus infection and diabetes: A complex bidirectional relationship
Ciardullo, S., Mantovani, A., Ciaccio, A., Carbone, M., Invernizzi, P., & Perseghin, G. (2022) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2022.109870 · Cited by 27
Miklánková, D., Marková, I., Hüttl, M., & Malínská, H. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1393946 · Cited by 21
Yasin, A., Nguyen, M., Sidhu, A., Majety, P., Spitz, J. A., Asgharpour, A., Siddiqui, M. S., Sperling, L. S., Quyyumi, A. A., & Mehta, A. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111650 · Cited by 20
The current landscape for diabetes treatment: Preventing diabetes-associated CV risk
Dardano, A., Bianchi, C., Garofolo, M., & Prato, S. D. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117560 · Cited by 18
Giannakogeorgou, A., Roden, M., & Pafili, K. (2025) · HORMONES · doi:10.1007/s42000-025-00701-y · Cited by 24
Self-citationFakhrolmobasheri, M., Abhari, A. P., Manshaee, B., Heidarpour, M., Shafie, D., Mohammadbeigi, E., Mozafari, A. M., & Mazaheri‐Tehrani, S. (2022) · Acta Diabetologica · doi:10.1007/s00592-022-01981-1 · Cited by 19
Bril, F., & Elbert, A. E. (2024) · Metabolism · doi:10.1016/j.metabol.2024.156066 · Cited by 17
Role of anti-diabetic medications in the management of MASLD
Isaacs, S. D., Farrelly, F. V., & Brennan, P. (2025) · Frontline Gastroenterology · doi:10.1136/flgastro-2024-102856 · Cited by 21
“Reduction in hepatic steatosis has been seen with dapagliflozin, 96 empagliflozin 97–99 and canagliflozin.”
Shojaei, F., Erfanifar, A., Kalbasi, S., Nikpour, S., & Gachkar, L. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-01882-8 · Cited by 22
“Based on these parameters and previous study [18], the required sample size was 70 patients for each group.”
Tsamos, G., Vasdeki, D., Koufakis, T., Michou, V., Makedou, K., & Tzimagiorgis, G. (2023) · Metabolites · doi:10.3390/metabo13040517 · Cited by 16
Shinozaki, S., Tahara, T., Lefor, A. K., & Ogura, M. (2020) · The Journal of Medical Investigation · doi:10.2152/jmi.67.280 · Cited by 16
“A randomized controlled trial from Germany reported a significant reduction of liver fat content in the empagliflozin treated group compared with the placebo group, and this trial did not show improvement in LDL cholesterol levels over 24 weeks (22).”
ResultKuchay, M. S., Choudhary, N. S., Mishra, S. K., & Misra, A. (2020) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2020.11.015 · Cited by 17
Nonalcoholic fatty liver disease
Makri, E. S., & Pοlyzos, S. A. (2022) · Journal of Atherosclerosis Prevention and Treatment · doi:10.53590/japt.02.1030 · Cited by 16
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: Causation or Association
Bali, A. D., Rosenzveig, A., Frishman, W. H., & Aronow, W. S. (2023) · Cardiology in Review · doi:10.1097/crd.0000000000000537 · Cited by 18
Bernhard, J., Galli, L., Speidl, W. S., & Krychtiuk, K. A. (2025) · Current Cardiology Reports · doi:10.1007/s11886-024-02185-5 · Cited by 19
“Several smaller trials have shown that commonly used SGLT2-inhibitors are able to lower liver fat content in patients with type 2 diabetes [82–84].”
Bril, F., Berg, G. A., Barchuk, M., & Nogueira, J. P. (2025) · Journal of Lipid and Atherosclerosis · doi:10.12997/jla.2025.14.1.5 · Cited by 17
Approach to the Patient With Nonalcoholic Fatty Liver Disease
Belfort‐DeAguiar, R., Lomonaco, R., & Cusi, K. J. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac624 · Cited by 16
SGLT2 Inhibitors in the Management of Cardio-Renal-Metabolic Syndrome: A New Therapeutic Era
Grigoriou, K., Karakasis, P., Nasoufidou, A., Stachteas, P., Klisic, A. N., Karagiannidis, E., Fyntanidou, B., Popovic, D. S., Patoulias, D., Antoniadis, A. P., et al. (2025) · Medicina · doi:10.3390/medicina61111903 · Cited by 23
Rajeev, S. P., Roberts, C. A., Brown, E. E., Sprung, V. S., Harrold, J. A., Halford, J. C. G., Stančák, A., Boyland, E. J., Kemp, G. J., Perry, J., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15257 · Cited by 17
Raggi, P., Milić, J., Manicardi, M., Cinque, F., Swain, M. G., Sebastiani, G., & Guaraldi, G. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117523 · Cited by 14
Kueh, M. T. W., Yeo, J. Q., Chen, Y., Chua, N. Y. Z., Koh, H. L., Khaw, S. P., Jabbar, H., Wang, J., Lee, K. S. S., Chin, Y. H., et al. (2026) · Liver International · doi:10.1111/liv.70747 · Cited by 16
Noah, A. A., El-Mezayen, N. S., El-Ganainy, S. O., Darwish, I. E., & Afify, E. A. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.176066 · Cited by 16
Malandris, K., Papandreou, S., Avgerinos, I., Karagiannis, T., Paschos, P., Michailidis, T., Liakos, A., Bekiari, E., Sinakos, E., & Τσάπας, Α. (2023) · HORMONES · doi:10.1007/s42000-023-00493-z · Cited by 14
Otunla, A. A., Shanmugarajah, K., Davies, A. H., & Shalhoub, J. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1355674 · Cited by 15
Dapagliflozin treatment alleviates fatty liver in patients with type 2 diabetes
Gao, X., Zhu, C., Zhu, W. M., & Wang, L. (2024) · Biomedical Reports · doi:10.3892/br.2024.1904 · Cited by 13
Cannarella, R., Rubulotta, M., Cannarella, V., Vignera, S. L., & Calogero, A. E. (2025) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2025.06.010 · Cited by 15
Bea, S., Jeong, H. E., Kim, J. H., Yu, O. H., Azoulay, L., & Shin, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.031 · Cited by 13
Recent updates on targeting the molecular mediators of NAFLD
Wang, J., Wang, L., Zhang, X., Zhang, P., Cai, J., She, Z., & Li, H. (2023) · Journal of Molecular Medicine · doi:10.1007/s00109-022-02282-4 · Cited by 15
Katsuyama, H., Hakoshima, M., Kaji, E., Mino, M., Kakazu, E., Iida, S., Adachi, H., Kanto, T., & Yanai, H. (2024) · Biomedicines · doi:10.3390/biomedicines12051001 · Cited by 15
“Moreover, it was suggested that semaglutide reduces hepatic fat content and has a preventative role against the progression of MASLD.”
BackgroundSelf-citationTang, X., Zhang, H., Wang, X., & Yang, D. (2022) · African Health Sciences · doi:10.4314/ahs.v22i3.42 · Cited by 12
Shi, Y., Kim, S. U., Yip, T. C., Tsochatzis, E. A., Petta, S., Nakajima, A., Hagström, H., Bugianesi, E., Chan, W., Boursier, J., et al. (2025) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2025.06.001 · Cited by 16
Yang, J. Y., Moon, A. M., Kim, H. H., Pate, V., Barritt, A. S., Crowley, M. J., Buse, J. B., Stürmer, T., & Alexopoulos, A. (2020) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2020.107706 · Cited by 12
“This trendmay reflect DPP4i's more neutral effect observed in NAFLD.12 Interestingly, serum dipeptidyl peptidase 4 (DPP4) levels are elevated in NASH, and are positively associatedwith histopathological grade and fibrosis.33,34 A recent randomized study by Yan et al comparing the efficacy of liraglutide, sitagliptin o…”
BackgroundInfluentialJianping, W., Xuelian, Z., Anjiang, W., & Haiying, X. (2021) · Journal of Clinical Gastroenterology · doi:10.1097/mcg.0000000000001556 · Cited by 13
Wang, Y., & Xia, N. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1897-6121 · Cited by 13
“…[30] 0.33 [0.22, 0.44] 13 % 0.29 < 0.001 Fadini 2017 [31] 0.37 [0.26, 0.47] 13 % 0.29 < 0.001 Eriksson 2018 [32] 0.37 [0.26, 0.47] 15 % 0.27 < 0.001 Kahl 2020 [33] 0.34 [0.23, 0.45] 19 % 0.21 < 0.001 Nandula 2021 [34] 0.35 [0.23, 0.46] 22 % 0.18 < 0.001 Phrueksotsai 2021 [35] 0.36 [0.24, 0.47] 21…”
BackgroundInfluentialKhaznadar, F., Petrovic, A., Khaznadar, O., Roguljić, H., Bojanić, K., Kuna, L., Siber, S., Smolić, R., Bilić-Čurčić, I., Wu, G. Y., et al. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12206561 · Cited by 12
Kuchay, M. S., & Misra, A. (2022) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2022.102446 · Cited by 12
The Association Between Total Percent Fat and Serum Uric Acid in Adults
Sun, J., Yue, C., Liu, Z., Li, J., & Kang, W. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.851280 · Cited by 12
Bea, S., Jeong, H. E., Park, S., Yu, O. H. Y., Chang, Y., Cho, J., Sinn, D. H., Cho, Y. M., & Shin, J. (2022) · Gut · doi:10.1136/gutjnl-2022-327504 · Cited by 12
Yadav, J., Ahsan, F., Panda, P., Mahmood, T., Ansari, V. A., & Shamim, A. (2024) · Current Diabetes Reviews · doi:10.2174/0115733998271026231127051545 · Cited by 13
Shikamura, M., Takayama, A., Takeuchi, M., & Kawakami, K. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15632 · Cited by 12
Mastrototaro, L., Apostolopoulou, M., Hartwig, S., Straßburger, K., Lipaeva, P., Trinks, N., Karusheva, Y., Gancheva, S., Trenkamp, S., Lehr, S., et al. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105471 · Cited by 13
Self-citationNon‐alcoholic fatty liver disease in type 2 diabetes – A specific entity?
Schröder, B., KAHL, S., & Roden, M. (2021) · Liver International · doi:10.1111/liv.14846 · Cited by 13
Self-citationAmjad, W., Malik, A., Qureshi, W., Dennis, B. B., Mumtaz, M., Haider, R., Jamal, S. M., Jaura, F., & Ahmed, A. (2022) · Gastroenterology Review · doi:10.5114/pg.2021.112365 · Cited by 17
“Another study from Germany demonstrated improvement of fat content with Empagliflozin; the steatosis was measured using volume-selective proton magnetic resonance spectroscopy (H-MRS) [30].”
MethodZou, C., Sun, Y., & Liang, J. (2022) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2022.102053 · Cited by 12
Ciccarelli, G., Giuseppe, G. D., Cinti, F., Moffa, S., Mezza, T., & Giaccari, A. (2023) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3668 · Cited by 11
Stan, S. I., Biciuşcă, V., Clenciu, D., Mitrea, A., Boldeanu, M. V., Durand, P., & Dănoiu, S. (2023) · Medicine and Pharmacy Reports · doi:10.15386/mpr-2629 · Cited by 18
“…carried out on patients with diabetes [124-127] that highlighted the beneficial role of Empagliflozin (EMPA), an SGLT2 with hypoglycemic effect [128,129], which improves any aspects of the MS and from antioxidant, anti-inflammatory, and anti-apoptotic properties [130] of UDCA aimed to evaluate…”
BackgroundNonalcoholic Fatty Liver Disease (NAFLD) for Primary Care Providers: Beyond the Liver
Leiva, E. G., & Bril, F. (2020) · Current Hypertension Reviews · doi:10.2174/1573402116999201209203534 · Cited by 12
Meyhöfer, S., Eckert, A. J., Hummel, M., Laimer, M. W., Roden, M., Kreß, S., Seufert, J., Meyhöfer, S. M., & Holl, R. W. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14616 · Cited by 12
Self-citationLee, M. H., Neeland, I. J., Rocha, N. D. A., Hughes, C., Malloy, C. R., & Jin, E. S. (2021) · Metabolism Open · doi:10.1016/j.metop.2021.100161 · Cited by 11
Hojná, S., Malínská, H., Hüttl, M., Vaňourková, Z., Marková, I., Miklánková, D., Hrdlička, J., Papoušek, F., Neckář, J., Kujal, P., et al. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.116520 · Cited by 11
Diagnosis and Management of MASLD: An Metabolic Perspective of a Multisystem Disease
Ganakumar, V., Halebidu, T., Goroshi, M., & Ghatnatti, V. (2024) · International journal of clinical metabolism and diabetes. · doi:10.1177/30502071231220779 · Cited by 10
“55-58 A meta-analysis by Sinha et al. confirmed a reduction in liver enzymes and liver fat content with SGLT2i, suggestive of a salutary effect of SGLT-2i on NAFLD in T2DM, probably driven by an improvement of glycemia and body weight, which in turn attenuates hepatic inflammation and hepatic fat…”
Zhang, J., Li, Y., Liu, Y., Ma, N., Qian, S., Chen, Y., Duan, Y., Xiang, X., & He, Y. (2024) · Cell & Bioscience · doi:10.1186/s13578-024-01267-9 · Cited by 11
Impact of Weight Loss on Metabolic Dysfunction Associated Steatohepatitis and Hepatic Fibrosis
Takawy, M., & Abdelmalek, M. F. (2025) · Current Diabetes Reports · doi:10.1007/s11892-025-01579-1 · Cited by 14
Erfanifar, A., Nikpour, S., Davoudi, Z., Jolfaei, P., Toreyhi, H., & Nasab, S. N. M. (2025) · BMC Endocrine Disorders · doi:10.1186/s12902-025-02098-6 · Cited by 13
“Similarly, Kahl et al. reported a ~ 22% relative reduction in liver fat after 24 weeks of empagliflozin in well-controlled diabetics [36].”
Metadata
- Authors
- Kahl, S., Gancheva, S., Straßburger, K., Herder, C., Machann, J., Katsuyama, H., Kabisch, S., Henkel, E., Kopf, S., Lagerpusch, M., Kantartzis, K., Kupriyanova, Y., Markgraf, D., van Gemert, T., Knebel, B., Wolkersdorfer, M. F., Kuss, O., Hwang, J.-H., Bornstein, S. R., Kasperk, C., Stefan, N., Pfeiffer, A., Birkenfeld, A. L., & Roden, M.
- Affiliations
- Deutsches Diabetes-Zentrum e.V. (DE)
- German Center for Diabetes Research (DE)
- GWT-TUD GmbH (Germany) (DE)
- University Hospital Heidelberg (DE)
- German Center for Diabetes Research, München-Neuherberg, Germany
- Institute for Clinical Diabetology, German Diabetes Center, Leibniz Institute for Diabetes Research at Heinrich-Heine University, Düsseldorf, Germany
- Landesapotheke Salzburg, Salzburg, Austria
- Paul Langerhans Institute Dresden (DE)
- Corresponding author
- Roden, Michael
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2019-09-20
- Volume
- 43
- Issue
- 2
- Pages
- 298-305
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2973671909
- Semantic Scholar
- d30e2aeb028f87844806b2c67eeca77b51e7e36a
- Cited by
- 360
- References
- 43
- Citations by year
- 2026: 47 · 2025: 59 · 2024: 58 · 2023: 59 · 2022: 54 · 2021: 46 · 2020: 35 · 2019: 1
- FWCI
- 27.61
- Type
- journal article
- Language
- en
- Open access
- Licence
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Site cant be reached (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- German Diabetes Center
- German Federal Ministry of Health
- German Center for Diabetes Research
- Boehringer Ingelheim
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- empagliflozin, SGLT2 inhibitors, type 2 diabetes, liver fat, hepatic steatosis, non-alcoholic fatty liver disease, insulin sensitivity, uric acid, high molecular weight adiponectin, weight loss, glycemic control, recent-onset diabetes, isotope dilution
- MeSH terms
- Adipose Tissue, Aged, Benzhydryl Compounds, Blood Glucose, Diabetes Mellitus, Type 2, Double-Blind Method, Female, Germany, Glucosides, Humans, Hypoglycemic Agents, Insulin Resistance, Liver, Male, Middle Aged, Placebos, Weight Loss, Down-Regulation, Adiposity, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.